U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07361562) titled 'A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors' on Dec. 03, 2025.
Brief Summary: This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpression.
Study Start Date: Dec. 30, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor, Adult
ERBB2 Altered Breast Cancer
ERBB2 Gene Amplification
HER2 Overexpression
Non-Small Cell Lung Cancer
HER2
In...